

Table S1 Patient characteristics and clinical outcomes

Patient #	Age (years)	Sex	AJCC TNM	Tumor location	Tumor size pre-treatment (mm)	Tumor size at 28-day follow-up after RT (mm)	Response to CRT (RECIST)	Pathologic response at time of surgery	Time to local/regional failure (months) [†]	Time to distant failure (months) [†]	Follow-up time (months) [‡]	Overall survival (months) [‡]
1	56	M	T3N2M0	Mid	§	§	§	Minimal response	46.5	46.5	46.7	–
2	69	F	T3N2M0	Mid	35	0	CR	Moderate response	46.7	46.7	83.8	–
3	36	M	T3N1M0	Low	26	9.9	PR	Complete response	53.3	53.3	60.0	–
4	71	F	T3N2M0	Low	20.6	21.7	PR	Moderate response	54.1	54.1	54.8	–
5	53	F	T3N2M0	Mid	41.6	15.4	PR	Moderate response	63.6	63.6	63.6	–
6	56	F	T4N2M0	Low	20.6	19.7	SD	Moderate response	57.3	57.3	57.3	–
7	52	M	T3N1M0	Mid	41.3	19.7	PR	Moderate response	58.4	58.4	64.6	–
8	54	M	T3N0M0	High	26.1	15.6	PR	Moderate response	51.5	51.5	54.7	–
9	56	M	T3N0M0	Low	43.3	23.9	PR	Minimal response	80.1	22.7	80.1	–
10	47	M	T3N1M0	High	39.4	0	CR	Moderate response	66.9	66.9	67.0	–
11	76	M	T3N0M0	High	51.6	21.6	PR	Complete response	54.9	5.95	54.9	54.9
12	42	M	T3N1M0	Low	32	0	CR	Moderate response	72.8	17.0	72.8	72.8
13	50	M	T3N0M0	Mid	36.6	26.8	SD	Moderate response	59.5	34.4	59.5	–
14	69	F	T3N1M0	Mid	§	§	§	Complete response	59.8	59.8	65.8	–
15	49	F	T3N1M0	High	32	15.8	PR	Minimal response	40.3	40.3	45.8	–
16	64	M	T3N1M0	Mid	20.8	16.3	SD	Moderate response	49.5	19.4	49.5	–
17	49	M	T3N0M0	Low	20.3	20.2	SD	Moderate response	21.9	21.9	22.0	–
18	60	M	T3N1M0	Mid	87.6	27.5	PR	Moderate response	58.7	58.7	58.7	–
19	50	M	T3N0M0	Mid	33.2	22.8	PR	Moderate response	76.6	76.6	76.6	–
20	59	M	T3N1M0	Mid	32.4	31.4	SD	Minimal response	48.7	48.7	48.9	–
21	53	M	T3N1M0	High	§	§	§	Moderate response	37.7	50.8	50.8	–
22	44	M	T4N1M0	Low	83.4	43.7	PR	No definite response	13.2	13.2	13.2	13.2
23	55	M	T3N2M0	Low	32.3	0	CR	Complete response	59.7	59.7	59.8	59.8
24	67	M	T3N0M0	Low	26.2	26.2	SD	Moderate response	61.3	61.3	67.7	–

[†], time from RT treatment to development of local progression or recurrence or most recent surveillance scans; [‡], time from RT treatment to last follow-up or death; [§], non-measurable lesions (longest diameter <20 mm on pelvic MRI). AJCC, American Joint Committee on Cancer; TNM, tumor, node, metastasis; RT, radiation therapy; CRT, chemoradiotherapy; RECIST, Response Evaluation Criteria in Solid Tumors; M, male; F, female; CR, complete response; PR, partial response; SD, stable disease; MRI, magnetic resonance imaging.

Table S2 Reported adverse events during treatment or at 28-day follow-up

System organ class	Adverse event	Number of patients affected					Number attributed to YIV-906	Number attributed to capecitabine	Number attributed to RT	Dose delayed or modified
		Grade 1	Grade 2	Grade 3	Grade 4	Grade 5				
Gastrointestinal	Nausea/vomiting	14	14	0	0	0	3	14	8	0
	Constipation	3	3	0	0	0	0	3	3	0
	Diarrhea	18	11	5	2	0	1	16	17	0
	BM urgency	2	2	0	0	0	0	1	2	0
	Fecal incontinence	1	0	1	0	0	0	0	1	0
	Rectal/anal hemorrhage	1	1	0	0	0	0	1	1	0
	Rectal/anal pain	15	14	1	0	0	0	1	15	0
Urinary	Urgency/frequency	5	5	0	0	0	0	0	5	1
	Incontinence	3	2	1	0	0	0	0	3	0
	Dysuria	4	4	0	0	0	0	0	4	0
General	Fatigue	13	12	0	1	0	1	11	11	0
Hematologic	Decrease in platelets or WBCs	13	6	3	4	0	1	14	11	0

RT, radiation therapy; BM, bowel movement; WBCs, white blood cells.